Modified Oncolytic Viruses for Tumor Antigen Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oncolytic therapies using viruses, such as herpes simplex virus (HSV), do not effectively induce immune responses in all tumors and patients, leading to variable treatment outcomes and limited survival benefits, particularly when combined with immune checkpoint blockade.
Innovation Solution
Oncolytic viruses engineered to express a fusogenic protein, like GALV-R-, and immune stimulatory molecules, such as GM-CSF or GITRL, enhance tumor antigen release and immune activation, improving direct oncolytic effects and synergizing with immune checkpoint blockade.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oncolytic viruses are used, then direct oncolytic effects are achieved, but immune response induction is insufficient and variable
Solution Approach 1:
The patent combines multiple functional elements into a single oncolytic virus platform: (1) tumor-selective replication capability, (2) fusogenic protein expression for enhanced cell lysis and antigen release, (3) immune stimulatory molecule expression (e.g., GM-CSF, GITRL), and (4) checkpoint blockade synergy. This merging approach ensures reliable immune response induction while consolidating complexity into an integrated therapeutic agent rather than multiple separate components.
Solution Approach 2:
The virus is engineered to express different functional proteins at different stages and locations: fusogenic proteins are expressed to enhance local tumor cell lysis and antigen release at the infection site, while immune stimulatory molecules are expressed to locally activate immune responses in the tumor microenvironment. This local quality differentiation ensures reliable immune induction without requiring systemic complexity.
2Productivity
If oncolytic viruses are used alone, then treatment is simple, but efficacy is limited and variable across patients
Solution Approach 1:
The oncolytic virus is pre-engineered to express immune stimulatory molecules and fusogenic proteins before administration, creating a primed therapeutic agent that is ready to induce reliable immune responses and enhance efficacy from the first dose. This preliminary action embeds the complexity of combination therapy effects into a single agent, achieving high productivity without requiring complex combination protocols.
Solution Approach 2:
The engineered oncolytic virus serves multiple functions simultaneously: (1) direct oncolytic activity through selective replication and lysis, (2) antigen release enhancement via fusogenic proteins, (3) immune stimulation through cytokine expression, and (4) checkpoint blockade synergy. This multi-functionality achieves high treatment efficacy across different patients without requiring complex combination regimens, as one agent performs all necessary therapeutic roles.
3Quantity of substance
If fusogenic proteins are expressed to enhance antigen release, then tumor antigen release increases, but viral replication control becomes more challenging
Solution Approach 1:
The patent uses tumor-specific promoters and regulatory elements as intermediaries to control fusogenic protein expression. These genetic intermediaries ensure that fusogenic proteins are expressed only in tumor cells with specific characteristics (e.g., hypoxia, high metabolic activity), thereby increasing antigen release selectively while maintaining viral replication control. The intermediary regulatory mechanisms prevent off-target expression that could compromise selectivity.
Solution Approach 2:
The fusogenic proteins are expressed with local quality control through tumor-specific promoter activation, ensuring that enhanced antigen release occurs only in the tumor microenvironment where viral replication is already selective. This localized expression maintains replication selectivity reliability while achieving high antigen release quantities specifically where needed.
Data Source
AI summary
The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule-encoding gene.